All News

Plaquenil.HCQ_.pills_.jpg (keep)

Hydroxychloroquine Shows No Benefit in Hospitalized COVID-19 Patients

d Jack Cush, MD

The NEJM reports on a controlled clinical trial showing patients hospitalized with Covid-19 given hydroxychloroquine (HCQ) do not have a lower incidence of death compared to those receiving routine care.

Read Article
podcast logo

RheumNow Podcast – Bad Disease & Bad Outcomes (10.9.20)

d Jack Cush, MD

Dr. Jack Cush Reviews the news and journal articles from the past week on RheumNow.com.

Read Article
vasculitis.Churg-Strauss_syndrome.wikipedia.jpg

Biologics Beneficial in Eosinophilic Vasculitis

d

Two biologic therapies showed promise in the treatment of refractory or relapsing eosinophilic granulomatosis with polyangiitis (EGPA) in a retrospective European study.

Read Article
GPA.jpg

Sustained Remission Off Therapy Unlikely in GPA

d Jack Cush, MD

A French Vasculitis Study Group analysis of their granulomatosis with polyangiitis (GPA) reveals that after 10 years, only 7% of GPA patients achieved sustained remission off therapy (SROT) and have never relapsed.

Read Article
hip.THR_.jpg

IL-1 Inhibition Alters Arthroplasty Rates

d Jack Cush, MD

A subanalysis of the CANTOS trial suggests that inhibition of interleukin-1β (IL-1β) can reduce rates of incident hip or knee replacement (THR/TKR) surgeries.

Read Article
Fracture%20bone.png (keep)

Fractures from Delays in Denosumab Reinfusions

d Jack Cush, MD

Denosumab is effective in osteoporosis when used on schedue, but research suggests that discontinuation leads to rapid reversal of effect; a new observational study has shown that delays in denosumab administration of more than 16 weeks results in an increased vertebral fracture risk, according t

Read Article
The RheumNow Podcast is up - Bad Disease & Bad Outcomes. COVID consequences, TNFi Switching in SpA, psychosis in lupus? Watch it here> https://t.co/ced3cKg5eB or listent to podcast on iTunes> https://t.co/FHJv01AAbC or SoundCloud> https://t.co/e4nWr3wECz

Links:

Dr. John Cush RheumNow ( View Tweet)

Congratulatons to Professor Ian McInnes on his appointment as Vice Principal & Head of College to the College of Medical, Veterinary and Life Sciences (MVLS), within the University of Glasgow. https://t.co/m3joegAEsK
Dr. John Cush RheumNow ( View Tweet)
Congratulations to #NIH's Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases (NIAID), on winning the 2020 Federal Employee of the Year award! #Sammies2020 https://t.co/S5n3M97o8d

Links:

Dr. John Cush RheumNow ( View Tweet)

Another case of COVID-19 Arthritis; 58 yoF w/ non-severe COVID-19, (by qRT-PCR ) had arthralgia, fever, cough, nausea, diarrhoea, dysgeusia, and devloped ankle arthritis CRP 7·36 mg/L, lymphopenia (1·29) persistent arthritis (by US) and +Sars-CoV-2 in SF. https://t.co/4Pg1Vq30EN

Links:

Dr. John Cush RheumNow ( View Tweet)

#WomenInMedicine now that we have data from ⁦⁦@NEJM⁩ - how do we help institutions work with women to address these challenges together? https://t.co/kEyegOCfE3
Victoria Shanmugam VickiShanmugam ( View Tweet)
Excellent review of IgG4-RD, @NatRevRheumatol IgG4-RD is indolent (afebrile, etc) but 60% of pts have irreversible damage at dx! Universal response to GC but 40% not in remission at 1yr; B-cell tx can bring about "dramatic response" Good read & topic: https://t.co/Mbrq7bFHk0 https://t.co/8oQF08qzit

Links:

Mike Putman EBRheum ( View Tweet)
Study of 193 Axial SpA pts with TNF inhibitor switching shows, using stringent outcome measures (ASDAS-ID) shows odds of responding to 2nd TNFi best w/ secondary TNFi failure (OR 7.3) or adverse events (OR 9.1), compared to primary TNFi failure. https://t.co/kpDelzBYRe

Links:

Dr. John Cush RheumNow ( View Tweet)

Study of 222 RA pts on MTX given anti-GMCSF (otilimab) 22·5 mg, 45 mg, 90 mg, 135 mg, 180 mg, or PBO weekly x 5 wks, then EOW. @wk 24 DAS28-CRP <2·6 5%, 16%. 19%, 14%, 14% respectively and 3% in PBO. Otilimab failed to meet primary endpoint. https://t.co/14QqyeTcuP

Links:

Dr. John Cush RheumNow ( View Tweet)

Comparison of 34,128 COVID and 84,585 influenza pts; COVID-19 patients have been more typically been male, younger, and have fewer comorbidities and lower medication use than flu. (data from USA, South Korea, Spain) https://t.co/VUzVxFdBra

Links:

Dr. John Cush RheumNow ( View Tweet)

Lockdown worsening; UK survey 678 patients musculoskeletal diseases pts in late April 2020 shows 53% worsening of Sx; 1/3 had clinic/hosp access probs problems & most (88%) had no probs w/ getting meds; but 44% needed others to help them get meds. https://t.co/3efmTdHhQx

Links:

Dr. John Cush RheumNow ( View Tweet)

Among 4766 mental health pts admited for Psychosis; 19% ANA tested and only 135 had a positive ANA >=1:160. (15% of those tested). Only 4 met 2019 ACR/EULAR criteria for SLE, and 2/4 met criteria for NPSLE. NPSLE prevalence was 1.5% in ANA+ psychosis Pts. https://t.co/c5C1VQaQAI

Links:

Dr. John Cush RheumNow ( View Tweet)

How pregnancy impacts nr-axSpA disease activity can vary from one woman to another, according to Eric Ruderman, MD, “I’ve had some patients who are better during pregnancy, and some who aren’t,” says Dr. Ruderman. Learn more about pregnancy and nr-axSpA: https://t.co/mC6YcG5lIx

Links:

NM Rheumatology NM_Rheumatology ( View Tweet)

To quash the virus, the immune system unleashes an arsenal. Sometimes these weapons turn inward and destroy healthy tissues. Combatting this friendly fire has become as crucial a part of the Covid-19 treatment strategy as subduing the virus itself. https://t.co/FrxVfSleEH

Links:

NYT Health NYTHealth ( View Tweet)

The AWIR San Diego, CA Virtual Summit CME Accredited : Worth 3.0 CEU Credits™ October 11th | Register Now: https://t.co/4vSqD0bxpk Join us on October 11th as we discuss Spondyloarthritis & the Spine, Telehealth regulatory updates, and more! For MD, NP, PA & PharmD Health Prof. https://t.co/QLXVJYjTD2

Links:

WOMEN IN RHEUM AWIRGROUP ( View Tweet)

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright 2024 All Rights Reserved.

×